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Objective: Supportive care needs in glioma patients often remain unrecognized, and
optimization in assessment is required. First, we aimed at assessing the support needed
using a simple structured questionnaire. Second, we investigated the psychosocial
burden and support requested from caregivers.
Methods: Patients were assessed at three centers during their outpatient visits. They
completed the Distress Thermometer (DT; score ≥ 6 indicated significant burden in
brain tumor patients), the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ)-C30+BN20, and the Patients’ Perspective
Questionnaire (PPQ) that assessed psychosocial distress as well as support requested
and received by patients for specific domains (e.g., family, doctor, and mobile care). In
each subgroup, patients’ caregivers were assessed simultaneously by a questionnaire
developed for the study. Multivariate backward logistic regressions were performed for
investigating predictors of patients’ request for support.
Results: Assessments were conducted for 232 patients. Most patients (82%) had a
high-grade glioma and a mean age of 52 years (range 20–87). The male to female ratio
was 1.25:1. According to the PPQ results, 38% (87) of the patients felt depressed; 44%
(103), anxious; and 39% (91), tense/nervous. Desired support was highest from doctors
(59%) and psychologists (19%). A general request for support was associated with lower
global health status (p = 0.03, odds ratio (OR) = 0.96, 95% CI: 0.92–0.99) according
to EORTC QLQ-C30. Most of the assessed caregivers (n = 96) were life partners (64%;
n = 61) who experienced higher distress than the corresponding patients (caregivers:
6.5 ± 2.5 vs. patients: 5.3 ± 2.4). When patients were on chemotherapy, caregivers
indicated DT ≥ 6 significantly more frequently than patients themselves (p = 0.02).
Conclusion: Our data showed that glioma patients and their caregivers were both
highly burdened. The PPQ allowed us to evaluate the psychosocial support requested
and perceived by patients, detect supportive care needs, and provide information at
a glance. Patients in poorer clinical condition are at risk of having unmet needs.
Renovanz et al. Results of a Multicenter Cross-Sectional Study
The caregivers’ burden and unmet needs are not congruent with the patients’ need for
support. In particular, caregivers of patients on chemotherapy weremore highly burdened
than patients themselves.
Keywords: supportive care needs, palliative care, glioma, brain tumor, self-assessment
INTRODUCTION
The prognosis in high-grade glioma patients remains poor, and
supportive care needs should be addressed in a timely manner.
The requirement for psychosocial support and early palliative
has not only become a focus of (neuro-) oncological research
(1–5), but is also incorporated in guidelines for the provision
of care for these patients (6, 7). Application of patient-reported
outcomes (PROs) has become essential in assessing the patients’
quality of life and their needs, distress, and psychosocial burden,
as well as supportive care needs (8). Recently, it has been
shown that monitoring symptoms via PRO measures can be
very helpful for cancer patients and even influence survival
(9, 10).
Palliative and end-of-life care are still partially neglected topics
in current neuro-oncological outpatient care. Seibl-Leven et al.
reported recently that palliative care in glioblastoma patients is
either not provided at all, or not in a timely fashion, leading to
a shortage of services for patients and caregivers (11). Adequate
assessment of unmet needs, early integration of palliative care
and timely end-of-life-care planning should be implemented as
clinical routine (12).
As glioma patients suffer from neurocognitive deficits caused
by both the disease itself and the treatment (13–15) they may
not always be able to answer PRO questionnaires. Furthermore,
as reported by our group and others, patients undergoing
chemotherapy or in a poor clinical condition may be missed by
PRO assessment; however, at the same time, they are those who
could particularly benefit from early supportive care (5, 16–18).
Therefore, we believe it is of utmost importance to adequately
identify glioma patients in need of supportive care.
Caregivers face challenging situations as well, sometimes even
more so than glioma patients. The neurological, psychological
and cognitive symptoms of patients with gliomas represent
significant challenges to their caregivers: Not only do they
have to cope with the diagnosis of the family member, with
the therapy and the knowledge that they will finally lose their
partner or parent or child, but also accept changes in roles,
relationships, social isolation, financial restriction and sooner or
later, have to take care of the partner or family member day and
night (19–23).
Therefore, the aims of our study were to (1) Assess support
received and needed by patients and (2) Assess support needed
by patients’ caregivers.
PATIENTS AND METHODS
Patients
During April 2015 to June 2016, patients at three German neuro-
oncological centers were approached during their outpatient
visits and asked to participate in the study. Inclusion criteria
were diagnosis of gliomaWHO grades II–IV regardless of disease
stage (initial diagnosis or recurrent disease), absence of aphasia
impairing communication or consent to the study, and given
informed consent. Patients were asked to complete several PRO
measures. Furthermore, demographic and clinical data were
recorded in a database.
PRO Measures Used
Distress Thermometer (DT)
The DT is a self-reporting screening instrument developed
by the National Comprehensive Cancer Network to evaluate
psychological distress on a visual analog scale (0–10 points).
A problem list with 40 items is included for patients to indicate
the area of concern (family, financial, and physical) (24). Studies
have proven its acceptance in oncological patients, and the
German version for brain tumor patients was first evaluated
by Goebel and Mehdorn (25). A score ≥6 indicates significant
burden in brain tumor patients.
European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire Core Module
for Cancer Patients Accompanied by the
Brain-Specific Module (EORTC QLQ-C30 + BN20)
The EORTC QLQ-C30 is a widely accepted questionnaire
applying a 4-point Likert scale to evaluate cancer patients’ quality
of life. Five functional, three symptom, and six single-item scales
as well as the global health status are investigated (physical, role,
emotional, social, and cognitive functioning; fatigue, nausea and
vomiting, pain; dyspnea, insomnia, appetite loss, constipation,
diarrhea, and financial difficulties). Its validity and reliability have
been proven in numerous clinical studies, and it is available in
85 languages. The additional module for brain tumor patients
(BN20) consists of 20 questions specifically assessing their
symptoms (3 neurological deficit scales, 1 future uncertainty
scale, treatment and disease-related symptoms) (26, 27). The
EORTC scores were calculated according to the user manual
(28). Each scale is scored from 0 to 100, with higher scores
indicating better functioning for functional scales and worse
symptoms for symptom scales. In our regression and correlation
analyses, we used the global health scale (GHS) as the primary
endpoint.
The Patients’ Perspective Questionnaire (PPQ)
The “Patients’ Perspective Questionnaire” (PPQ) is a
questionnaire assessing patients’ current status of support
received, its subjective benefit and further needs. It was adapted
for brain tumor patients based on a questionnaire used by
Singer et al. (29). They applied several versions, whereas in
our study we combined them into one questionnaire, added
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questions and items of probable interest to glioma patients
according to the authors’ experiences. This resulted in one
questionnaire comprising three parts: Part I: The first 9 items
assessed psychosocial distress (sad /worried /angry /tense
/hopeful /burdened by disease/ burdened by other problems/
sufficiently supported/ sufficiently informed) by 5-step Likert-
scales (scoring from 1 = not at all to 5 = very much) and if
support was requested by the patient with regard to the respective
item (“I need support for. . . .”: yes/no). The latter questions were
considered for the general request for support if one or more
item was answered with “yes.” The next 10 items (Part II)
assessed support provided and its subjective benefit on a 5-step
Likert scale (scoring from 1 = support was not helpful at all to
5= support was very helpful). The last 7 items (Part III) recorded
support requested currently by the patients (from doctors,
psychologist, social worker, and so on) with dichotomous answer
possibilities (yes/no). Further support currently requested by
any profession or next of kin was considered positive if one
or more answers were “yes.” The questionnaire is provided as
Supplement 1.
The Questionnaire for the Caregivers/Caregivers’
Perspective Questionnaire (CPQ)
In order to provide a questionnaire for glioma patients’ caregivers
in line with the PPQ with regard to structure and practicability,
we combined elements and items after conducting a literature
search and using an expert panel in the study group. We first
applied it as a pilot study in family members volunteering
during an information-sharing event for brain tumor patients.
According to their anonymous feedback, the questionnaire
was adapted with respect to wording, font size and item
specification. The final version of the questionnaire is provided as
Supplement 2.
Part I assessed the psychological distress on a visual analog
scale (0–10 points) according to the DT applied to patients.
Further, possible problem-items were provided similarly to the
DT item list with dichotomous choices with regard to practical,
family or emotional problems (24). In part II, we incorporated
two questions with regard to quality of life and global health
with Likert scales scoring from 1 to 7 according to the items
29 and 30 of the EORTC QLQ-C30 questionnaire (26). Finally,
part III provided a list of items recording the support requested
by caregivers (psychologists, social care, doctor, physiotherapy,
dietician, self-help, friends, family members, palliative care). The
questionnaire further included a question if an explanation of any
term in the questionnaire was needed (Supplement 2).
Patients’ and Caregivers’ Assessment
Patients completed the DT, EORTC QLQ-C30+BN20 and
the PPQ by themselves. Further, patients were asked directly
by the attending neuro-oncologist during the patient-doctor
consultation if they would like support by a psychologist.
Neuro-oncologists also indicated and recorded their own
assessment with regard to patients’ unmet psycho-oncological
needs independent of the assessment by questionnaires after
having obtained the current medical history.
In a subgroup, patients’ caregivers were assessed
simultaneously by the CPQ developed for the study.
Statistical Analysis
Demographic and tumor-related data, as well as Karnofsky-
Index, were analyzed descriptively. Explorative Spearman’s rho
correlations betweenDT score as well as GHS and general request
for support or request for support by doctors were performed.
Multivariate logistic regressions were performed with regard
to “request for support in general” as well as “request for support
by doctors” and “by other health care professionals.” Clinical
and demographic factors probably influencing request for
support were selected content driven by the authors as follows:
sex (male/female), living situation (alone/in relationship),
educational level (university degree/no university degree),
WHO grade (low-grade/high-grade glioma), Karnofsky-Index
(continuous variable, score 0–100), on chemotherapy (yes/no),
GHS (continuous variable, EORTC QLQ-C30, score 0–100), DT
score (continuous variable, score 0–10), surgery for recurrent
disease (yes/no), and age (continuous variable, 25–85). The
statistical analyses were performed using SPSS version 22 (IBM
Corp., Armonk, NY).
Ethics
The study was performed in accordance with national law,
institutional ethical standards, and the Declaration of Helsinki
after approval of the study protocol by the local ethics committees
(Mainz, Germany and Ulm/Günzburg, Germany [No: 837.349.15
(10117)]. All patients provided written informed consent prior to
data assessment.
RESULTS
Patients
Two hundred and thirty-two patients were assessed and 84%
of the patients had a high-grade glioma. Mean age was 52
years (range 25–85). Male to female ratio was 1.25:1. Most of
the patients were in a relationship and 30% (n = 71) had a
higher education level. Mean Karnofsky-Index was 79 and 52%
of the patients were on chemotherapy during assessment. Further
details are provided in Table 1.
Patients’ Perceived and Requested
Support According to the PPQ
We observed that 38% (87) of patients felt depressed (indicated
≥ 3 on the Likert scale), 44% (103) were anxious and 39%
(91) were tense/nervous. Fifty-nine percent (138) reported
to be adequately informed about the disease and therapy
and 77% (180) of the patients felt sufficiently supported
(Table 2).
Patients’ support was reported to be highest from family
(75%) and doctors (e.g., physician or attending neuro-
oncologists, 68%). Only 13% were supported by psychologists.
The support was mostly reported as helpful with highest
mean scores being that of family and friends (mean score
> 4), followed by doctors, outpatient care services and
physiotherapists.
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TABLE 1 | Clinical and demographic data of the patient sample and results of the
psychosocial assessment using the Distress Thermometer (DT; score ≥ 6
indicated significant burden in brain tumor patients), the European Organization
for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ)-C30+BN20, and the Patients’ Perspective Questionnaire (PPQ).
Variable Patients n = 232 (100%)
AGE IN YEARS
Mean (SD; min, max) 52 (14; 20, 87)
Sex, n (%)
Male 129 (56)
Female 103 (44)
LIVING SITUATION, n (%)
Single 49 (21)
In relationship 75 (72)
Unknown 8 (7)
EDUCATION LEVEL
University degree 71 (30)
No university degree 151 (66)
Unknown 10 (4)
WHO-GRADE, n (%)
LGG (WHO I◦+II◦) 35 (16)
HGG (WHO III◦+IV◦) 190 (84)
TUMOR LOCALIZATION I, n (%)
Frontal 99 (43)
Temporal 57 (25)
Parietal 31 (13)
Occipital 12 (4)
Other 17 (8)
Unknown 16 (7)
ONGOING CHEMOTHERAPY, n (%)
Yes 111 (48)
No 121 (52)
SURGERY FOR RECURRENT TUMOR, n (%)
Yes 57 (25)
No 140 (60)
Missing 35 (15)
KARNOFSKY-INDEX
Mean (SD, range) 79 (16; 40–100)
TIME SINCE DIAGNOSIS IN MONTHS
Mean (SD, range) 42 (54; 4–288)
Median 19
VALUE OF DISTRESS-THERMOMETER*
Mean (SD, range) 5.0 (2.5; 0.0–10.0)
< 6 (n, %) 126 (54)
≥ 6 (n, %) 95 (41)
Missing 11 (5)
SELECTED EORTC QLQ-C30 AND EORTC QLQ-BN20 SCORES, MEAN
(SD)
C30 Global Health Status/QoL 57.4 (23.0)
C30 Physical functioning 68.8 (30.1)
C30 Role functioning 57.3 (36.4)
C30 Emotional functioning 60.4 (28.0)
C30 Cognitive functioning 58.3 (32.7)
C 30 Social functioning 54.3 (35.9)
(Continued)
TABLE 1 | Continued
Variable Patients n = 232 (100%)
C 30 Fatigue 46.3 (32.0)
C 30 Pain 23.4 (28.0)
BN20 Future uncertainty 43.9 (29.9)
BN20 Motor dysfunction 25.0 (27.1)
BN Communication 31.7 (32.4)
BN Headache 29.7 (32.2)
LGG, low grade glioma; HGG, high grade glioma.
Desired support was highest from doctors (59%) and
psychologists (19%) as well as from dieticians (15%, Table 2).
Patients’ Requested Support in
Comparison to DT, GHS, and Clinical
Condition
Patients requesting support according to the PPQ generally
showed higher DT scores (according to DT, p = 0.006,
rs = 0.20), lower GHS (according to EORTC QLQ-C30,
p < 0.001, rs = −0.34), and lower Karnofsky indices (p = 0.03,
rs = −0.18). The request for support was further associated
with patients’ wish for psychological intervention when asked
directly (p = 0.03, rs = 0.27), and the neuro-oncologist’s
clinical assessment of patients’ unmet needs (p = 0.001,
rs = 0.24).
Factors Associated With Current
Requested General Support According to
the PPQ
With regards to the request for support in general, we observed
that patients reporting “lower GHS” were at higher risk for unmet
needs (p = 0.03, odds ratio (OR) = 0.96, 95% CI: 0.92–0.99), as
assessed by logistic regression analysis (step 5). Patients “living
alone” indicated higher request for support; however, this was not
significant. Educational level, WHO grade, Karnofsky-Index, on
chemotherapy, DT score, surgery for recurrent disease and age
were not significantly associated with the request for support in
general.
Factors Associated With Current
Requested Support by Doctors According
to the PPQ
Logistic regression analyses revealed that “living situation/not
in partnership” was associated with request for support by
doctors according to the PPQ (living situation/in partnership
p = 0.01, OR = 0.06, 95% CI: 0.01–0.53). Further, we
observed a tendency of patients “on chemotherapy” to
wish for greater support; however, this was not significant.
Request for support from physicians was not significantly
associated with educational level, GHS, sex, WHO grade,
Karnofsky-Index, DT score, surgery for recurrent disease and
age.
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TABLE 2 | Results of assessments in 232 patients using the PPQ.
Item Do you feel…?
(Mean on Likert scale*)
Support requested
(n, %)
PART I: MOOD AND WELL-BEING
Sad/depressed 2.3 (1.2) 37 (16)
Worried/anxious 2.5 (1.2) 36 (16)
Angry 2.0 (1.2) 28 (12)
Tense/nervous 2.3 (1.2) 33 (14)
Hopeful 3.3 (1.2) 25 (11)
Burdened by disease 2.9 (1.3) 44 (19)
Burdened by other
problems
2.2 (1.3) 27 (12)
Sufficiently supported 3.9 (1.3) 33 (14)
Sufficiently informed 3.5 (1.3) 49 (21)
Profession Received support
(n, %)
If yes, how helpful?
(Mean on Likert scale#)
PART II: RECEIVED SUPPORT
Doctor 157 (68) 3.9 (1.0)
Outpatient
care/palliative services
46 (20) 3.8 (1.1)
Physiotherapist 54 (23) 3.6 (1.3)
Social service 27 (12) 3.4 (1.6)
Psychologist 31 (13) 3.3 (1.6)
Pastor 11 (5) 2.9 (1.7)
Dietician 12 (5) 2.8 (1.4)
Support group 4 (2) 2.3 (1.6)
Family 174 (75) 4.5 (0.9)
Friends 156 (67) 4.2 (1.0)
Profession Requested support (n, %)
PART III: REQUESTED SUPPORT
Doctor 137 (59)
Outpatient
care/palliative services
31 (13)
Social service 26 (11)
Psychologist 43 (19)
Pastor 10 (4)
Dietician 34 (15)
Support group 23 (10)
In part I, patients indicated their psychological well-being and mood as well as satisfaction
and unmet information needs. In part II, patients indicated received support and rated how
helpful the support was. In part III, patients indicated by which profession he/she needed
support. *Likert scale 1–5 with 1 = not at all and 5 = very much. #Likert scale 1–5 with 1
= not at all helpul and 5 = very helpful.
Factors Associated With Current
Requested Support by Any Health Care
Profession According to the PPQ
With regard to request for support by any health care
profession, logistic regression revealed that “living situation/not
in partnership” as well as “university degree” were associated with
wish for support by any health care profession according to the
PPQ; “living situation/in partnership” was protective (p = 0.01,
OR = 0.076, 95% CI: 0.10–0.57), whereas having “university
degree” posed a higher risk (p = 0.04, OR = 7.86, 95% CI: 1.10–
56.08). There was no significant association between requested
support from any health care profession and sex, GHS, WHO
grade, Karnofsky-Index, on chemotherapy, DT score, surgery for
recurrent disease and age.
The Caregivers’ Burden
In a subgroup of 96 patients, their caregivers completed the CPQ.
Patients’ age in this subgroupwas 56 years (SD 14.8, range 19–84).
Most of the caregivers (64%, n= 61) were life partners.
Caregivers’ DT mean was higher than the DT mean of the
corresponding patients (caregivers: DT = 6.5, SD = 2.5 vs.
patients: DT mean = 5.3, SD = 2.4). Similarly, a DT score ≥6
was reported more frequently by caregivers (55%, n = 53) than
patients (47%, n = 37). Simultaneously, according to the CPQ,
caregivers were highly burdened: 48% indicated to be anxious,
54% were sad and 70% reported concerns/worries. Practical
problems were mostly problems with insurance or financial
problems (24%), mobility and transport (38%) and working
situation (25%). The changes in relationship (32%) and problems
in interactions with spouse or life partner (28%) were frequently
reported. Further results are presented in Table 3.
When patients were on chemotherapy, caregivers indicated
DT ≥ 6 significantly more frequently than the patients
themselves (patients: 33%, n = 13 vs. caregivers: 59%, n = 23,
p= 0.02, Fishers’ exact test).
Caregivers’ Requested Support
Twenty-eight percent (n= 26) of caregivers indicated a moderate
and 14% (n = 13) a poor quality of life (mean of all assessments
QoL: 4.4, and global health: 4.7 on a Likert scale 1–7). Requests
for support came mostly from family (26%), doctors (24%),
psychologists (15%), physiotherapists (15%) as well as social
service (13%). Table 3 presents results in more detail.
DISCUSSION
In our study, we were able to apply the PPQ to glioma patients
and assess support received and needed by patients as well
as evaluate the accompanying caregivers by a study-specific
questionnaire in a subgroup of patients. We found clinical and
demographic factors (e.g., GHS, living situation, and university
degree with regard to education) to be associated with higher
wish for support, either global or support by a specific profession.
Caregivers were even burdened more highly and needed support
as well.
Patients and Required Support
In our sample of glioma patients, we observed that the
male to female ratio, general conditions expressed by the
Karnofsky-Index and the high rate of high-grade gliomas (HGG)
represented patients seen by neuro-oncologists in outpatient
settings in general. However, as we did not assess the percentage
of patients refusing the assessment, we are unable to reflect on
the reasons for refusal (e.g., the assessment comprising three
questionnaires might not have been well-accepted and probably
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TABLE 3 | Results of assessments in 96 caregivers using the self-developed
questionnaire.
PART I: DISTRESS AND PROBLEMS
Distress mean (SD; median) 6.5 (2.5, 6)
Problems with… n (%)
Child Care 11 (11)
Housing situation 10 (10)
Insurance/finance 23 (24)
Mobility/transport 36 (38)
Working/education 24 (25)
Interaction with children 10 (10)
Interaction with life partner 27 (28)
Interaction with parents 12 (13)
Depression 12 (13)
Anxiety 46 (48)
Nervousness 45 (47)
Sadness 52 (54)
Worries 67 (70)
Changes in relationship 31 (32)
PART II: QUALITY OF LIFE
Quality of Life of caregiver* 4.4 (1.5)
Global health of caregiver* 4.7 (1.4)
PART III: REQUESTED SUPPORT
Profession n (%)
Psychologist 14 (15)
Social service 12 (13)
Doctor 23 (24)
Outpatient care 13 (14)
Physiotherapist 14 (15)
Pastor 4 (4)
Dietician 10 (10)
Self-help group 4 (4)
Family 25 (26)
Palliative services 8 (8)
Request for further explanation of terms 3 (3)
In part I, caregivers indicated their distress and problems. In part II, caregivers indicated
their quality of life and health status. In part III, they indicated by which profession he/she
needed support.
*Likert scale 1–7 with 1 = extremely poor and 7 = very good.
too demanding). Seibl-Leven et al. reported a relatively high
refusal and drop-out rate in their field study (11). Further,
in a previous study by our group, we observed that patients
refusing an assessment or dropping out of an observational
study were more often with recurrent diseases, poorer clinical
condition and harbored more often a glioblastoma (18, 30).
Therefore, we should take into account that a certain percentage
of patients probably with unmet needs may have been missed
by our assessment and assume that we observed a selection
of glioma patients, leading to a lower generalizability of the
results.
In general, high burden and a strong wish for support for
certain mental/emotional states (e.g., worries and depression)
were indicated by the patients using the PPQ, which was also
reflected by the fact that higher DT scores were associated with
more frequent requests for support. This is in line with other
studies and emphasizes how demanding comprehensive care for
glioma patients is (2, 11, 31–34).
Interestingly, 15% of the patients required support by
dieticians. While rarely addressed by neuro-oncologists, this
aspect should be taken into account when planning supportive
care for glioma patients as they frequently suffer from dysphagia
in the final phase of the disease (35, 36).
Although many patients suffered from depression, worries
and sadness, only 13% were supported by psychologists and
20% by outpatient/palliative care services, and only 19% and
13% required support from these respective professions. One
reason for this finding could be that patients felt stigmatized
when they experienced psychological problems and hesitated
to ask for and accept support. Doctors rarely refer patients
proactively for psychosocial support or palliative care timeously.
Ideally, the treatment team is multidisciplinary from the very
beginning of the disease trajectory. Even if the patients are
not healed, this team can still support the patients together
(5, 7, 36). This is also strengthened by the fact that according
to the findings from the PPQ in our study, many patients and
caregivers required general support as well as support from
doctors relatively often. As we did not define the specialist
disciplines (e.g., neurologist, family doctor or oncologist) in
the questionnaire, it remains difficult to interpret this high
percentage. It may probably include other disciplines: Patients
might hesitate to indicate the need of psychological support;
however, they might prefer to indicate support by doctors.
The high rate of required support by doctors compared to
other disciplines could be further due to the timing of the
assessment. All patients were assessed prior to the appointment.
Thus, potentially relevant questions were not addressed. Patients
participating in this study may have attempted to be a “compliant
patient” which may have introduced a certain bias in our study.
This is also a possible explanation for the finding that patients
rated the support by doctors as “helpful” in part II of the
PPQ.
Patients seemed to be not well informed. This is of concern
and needs to be considered seriously, and as already reported
by other studies on patient-doctor consultations in (neuro-)
oncology, improvement in communication skills is required
(37). Glioma patients suffer from neurocognitive deficits and
comprehension can be impaired (38, 39). Further, due to the lack
of data and effective treatment options for patients with recurrent
gliomas, patients may feel that they are under-informed and hope
for new therapeutic options (40).
Distress, GHS and Request for Clinical
Support
We found a correlation of elevated DT, higher burden of
patients and request for clinical support. Furthermore, the
wish of patients when asked directly and the assessment of
attending neuro-oncologists were both associated with request
for general support. It is well known that doctors’ views are
not always congruent with the patients’ views with regard to
psychosocial distress and unmet needs (2). However, our data
show that if there is no time for an extensive psychosocial
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assessment or patients are unable to complete questionnaires
during the routine clinical visit, a higher level of distress
directly indicated by the patient on a visual analog scale
(which should be feasible for most of the patients) may
signal unmet needs. Of note, the doctor in charge has to
find out during the consultation the reasons for the distress
and the areas of unmet needs. In our opinion, a routinely
implemented question on distress during the consultation could
draw attention to the patients’ problems and initiate support
whenever another type of screening (e.g., with questionnaires) is
not possible.
Factors Associated With Required Support
We observed several clinical and demographic factors to be
associated with required support. As also shown by others,
patients in poor general condition (as perceived by themselves
and expressed in our study by GHS) require greater support
(34, 41).
In times of increasing social isolation, it seems to be an
important finding of our study that patients living alone were
at risk of higher unmet needs. Attending neuro-oncologists and
physicians should consider the social situation of patients in
order to initiate support timeously, particularly as patients with
gliomas (as well as their families) are at risk for social isolation
per se (42, 43).
Interestingly, patients with higher educational level longed
for more support by any health care profession than did other
patients. Possibly, they may have been better informed than
the others or needed further support to deal with information
obtained by themselves (e.g., via the internet). Presumably, all
patients deal intensively with the poor prognosis, the clinical
deficits, the neurocognitive impairment and psychological
burden; however, those with higher education verbalize their
questions better than the others. Although our analyses have to
be regarded as exploratory, we observed similar results as others
and the factors could serve as features signalizing patients with
unmet needs to the doctors in charge (22, 34).
Caregivers’ Burden
As in other studies, the caregivers of our patients reported
high distress, even higher than that of the patients (1, 2, 22,
23). Our caregivers were mostly life partners accompanying
their relative to the consultation. It is well known that
in glioma patients, family problems occur due to role
changes, or changes in relationships. Demanding financial
situations and practical issues also lead to tremendous burden
in caregivers along the disease trajectory—reflected in our
data as well (e.g., 70% of the caregivers reported to be
worried). Hence, special screening for caregivers is required
using instruments such as our questionnaire which was
well accepted. When patients are on chemotherapy, neuro-
oncologists should take into account that mostly caregivers
organize the family life, take care of the patients and
are in charge when patients suffer from side effects. In
order to relieve caregivers, early integration of palliative
care, outpatient services, social services and interdisciplinary
treatment (during ongoing tumor-specific therapies) are required
(44–47).
Caregivers’ Requested Support
Although caregivers reported high burden, only a minority
wished for support by any profession. This may be partially due
to functional coping strategies [e.g., high expectation of self-
efficiency (20)] as well as feelings such as shame and fear about
being unable to manage. These hinder caregivers to requesting
and/or accepting “external help.” Some patients may also refuse
outpatient care services as they do not like to accept the help
of people they do not know and wish to stay at home in the
final phase as well (36). This could lead to an enormous burden
for caregivers when not supported by outpatient palliative care,
which is the task of the doctor in charge (mostly physicians
and neuro-oncologists) to initiate in a timely and sensitive way
(45).
Strengths and Limitations of the Study
Of note, this is the first study that applied the two questionnaires
in glioma patients and caregivers simultaneously in a multicenter
study, with both questionnaires found to be useful for clinical
and research purposes. However, the study does have several
limitations.
The study required patients to be fit enough to complete
several questionnaires. Therefore, patients in advanced stages
of the disease and with cognitive deficits were not included,
even though they might be the ones with the highest
level of distress and need for supportive care. Shorter
assessments are required for such patients. The study was
a cross-sectional study and did not investigate the course
of needs and distress during the disease trajectory. PPQ
and CPQ were not validated instruments; therefore, the
results should be interpreted with caution. Furthermore, the
patient population was in a heterogeneous disease stage
and current treatment. However, this can also represent a
certain benefit as the results translate well to the general
outpatient population seen at neuro-oncological centers. The
content-driven selection of probable influencing clinical and
demographic factors with regard to requested support for
explorative correlation and logistic regression analyses reduced
the statistical strength.
CONCLUSION
Our data show that glioma patients are highly burdened,
and doctors play a crucial role in initiating these patients’
psychosocial care and support. The PPQ allows us to evaluate
the support requested and perceived by the patients, to detect
supportive care needs and provide information at a glance.
We observed clinical factors (e.g., when patients live alone
in relation to support by doctors, lower GHS with regard to
general requested support) and demographic factors (e.g., living
alone or higher educational level with regard to support
by any profession) that are possibly associated with unmet
needs.
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Of note, the patients’ needs do not always reflect the caregivers’
situations. Especially, caregivers of patients on chemotherapy
are more burdened than patients themselves. Therefore, either
using a questionnaire or questioning during consultation, regular
assessment of relatives/caregivers accompanying the patient is
required.
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